Congenital absence of norepinephrine due to CYB561 mutations
Cyndya A Shibao1, Emily M Garland1, Bonnie K Black1
1From the Departments of Medicine (C.A.S., E.M.G., B.K.B., D.R., I.B.), Neurology (D.R.), and Pharmacology (D.R.), and the Vanderbilt Autonomic Dysfunction Center (C.A.S., E.M.G., B.K.B., D.R., I.B.), Vanderbilt University Medical Center, Nashville, TN; Autonomic & Neurovascular Medicine Center (C.J.M.), Hospital of St John & St Elizabeth; St Mary's Hospital (C.J.M.), Imperial College Healthcare Trust; Institute of Neurology/University College London (C.J.M.), UK; Department of Ophthalmology and Visual Sciences (M.B.G.), School of Medicine, University of Alabama at Birmingham; and Johns Hopkins All Children's Hospital (A.W.R.), St. Petersburg, FL.
Objective:
Cytochrome b561 (CYB561) generates ascorbic acid, a cofactor in the enzymatic conversion of dopamine to norepinephrine by dopamine β-hydroxylase. We propose that the clinical relevance of this pathway can be revealed by characterizing the autonomic and biochemical characteristics of patients with CYB561 mutations.
Methods:
We performed autonomic evaluations in 4 patients with lifelong orthostatic hypotension in whom CYB561 mutations were determined by genomic sequencing.
Results:
Patients had disabling lifelong orthostatic hypotension (OH) and impaired blood pressure response to the Valsalva maneuver (VM), with exaggerated hypotension during phase 2 and lack of overshoot during phase 4. Heart rate ratios for sinus arrhythmia and the VM were normal. Plasma norepinephrine and metabolites were undetectable, and plasma dopamine and metabolites were normal. Droxidopa restored norepinephrine levels and improved OH. Patients 1 and 2 were sisters and homozygous for a nonsense mutation in exon 2, c.131G>A, p.Trp44 (Circ Res 2018). Their brother (patient 3) died at age 16 and his DNA was not available. Patient 4 was compound heterozygous; one allele had a missense mutation in exon 2, c157C>T, p.His.53Tyr, and the other had an exon 2 deletion.
Conclusion:
CYB561 deficiency is characterized by selective sympathetic noradrenergic failure with lifelong, disabling OH but with normal sympathetic cholinergic (sweating) and parasympathetic (heart rate regulation) functions. We report a novel case of CYB561 deficiency due to an exon 2 deletion in one allele and a missense mutation in the other. These patients highlight the critical role CYB561 plays in sympathetic function and cardiovascular regulation.
Related Concept Videos
Inborn Errors of Metabolism
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Incomplete Dominance
Drugs Affecting Neurotransmitter Release or Uptake
Smooth Endoplasmic Reticulum
The ER provides optimal conditions for synthesizing steroid hormones and lipids, such as phospholipids and triglycerides. Traditionally, lipid metabolism was considered to be a smooth ER function. However, there is no direct evidence to prove that rough ER is completely excluded from lipid...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...


